The "PDA" counterion argument that arginate salt formulation constitutes a distinct compound outside the Category 2 ruling has not been validated by any FDA guidance as of this writing
PAS is supporting research to explore more flexible and less resource-intensive methods, including: Self-Administration : Advocating for more patients (if they are willing) to be taught how to administer their own injections safely at home, reducing reliance on GP appointments
View Study PCO-02 Safety and Pharmacokinetics Trial (Phase 1)
This product is neither a drug, food, nor cosmetic, and must not be misrepresented, misused, or mislabeled as such
promote new blood vessel formation (angiogenesis)
Too many hoops to jump through, outdated warnings based on fears that never panned out, and a treatment that's technically classified alongside ketamine as a controlled substance